Aquestive Therapeutics (NASDAQ:AQST) Issues Earnings Results, Misses Expectations By $0.01 EPS

Aquestive Therapeutics (NASDAQ:AQST) posted its quarterly earnings results on Monday. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01), Zacks reports. The company had revenue of $13.54 million for the quarter, compared to the consensus estimate of $12.69 million. During the same period in the prior year, the company earned ($0.03) EPS.

Aquestive Therapeutics Price Performance

AQST stock traded up $0.09 during trading on Thursday, hitting $5.16. 682,012 shares of the stock traded hands, compared to its average volume of 1,750,238. Aquestive Therapeutics has a 1 year low of $1.55 and a 1 year high of $6.23. The firm’s 50 day moving average is $4.91 and its two-hundred day moving average is $3.83. The stock has a market cap of $469.87 million, a price-to-earnings ratio of -11.27 and a beta of 2.82.

Wall Street Analysts Forecast Growth

AQST has been the subject of several research reports. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a report on Wednesday. JMP Securities reiterated a “market outperform” rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Finally, Leerink Partners increased their price target on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $8.83.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.